Hillstream BioPharma to Participate in Two Major Industry Conferences

Biotechnology company, Hillstream BioPharma (Nasdaq: HILS), will participate in two major industry conferences in April 2023.

The company will present at the 2023 BioNJ BioPartnering Conference which will take place from April 17-18, 2023 in Somerset, New Jersey. Hillstream’s management team will also attend the CPHI North America Conference being held April 25-27, 2023 in Philadelphia, Pennsylvania.

Highlights

  •  As part of its presentation, Hillstream will discuss recent operational highlights, and updates on its immuno-oncology pipeline candidates, including Its lead drug candidate HSB-1216 and the outlook for initiating a clinical study in the second half of 2023, and the company’s emerging immune-oncology pipeline led by HSB-3215, an anti-HER2 monoclonal antibody.
  • CEO, Randy Milby will hold one-on-one meetings with analysts and qualified investors at both conferences.
  • Earlier in 2023, Hillstream entered an exclusive option agreement with Applied Biomedical Science Institute to license technology to develop proprietary multi-format biologics against drug resistant cancers including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer.

 About Hillstream BioPharma

Hillstream BioPharma, Inc. is a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis and immuno-oncology targeted novel biologics. Ferroptosis is an emerging new anti-cancer mechanism resulting in iron mediated cell death. The Company is on track to submit an investigational new drug application (IND) and initiate a clinical study for HSB-1216 as a potential treatment for drug resistant cancers in the second half of 2023. Hillstream’s immuno-oncology pipeline includes HSB-3215 and HSB-1940 Quatrabody™, an anti-PD-1 novel biologic which could be coated onto Quatramers. Hillstream’s Quatramer™ proprietary tumor targeting platform extends duration of action and minimizes off-target toxicity for biologics, mRNA, peptides, small molecules and other modalities in the tumor microenvironment.

Share This Article

 

About the Author

Hillstream BioPharma to Participate in Two Major Industry Conferences

Editor Prism MarketView